1. Introduction {#s0005}
===============

*Pseudomonas aeruginosa* is a gram-negative bacillus that is rapidly becoming one of the major causes of opportunistic and nosocomial infections. Nosocomial infections caused by *Pseudomonas aeruginosa* have become a worldwide problem. *P. aeruginosa* infections are associated with increased mortality and morbidity, particularly in susceptible patients with compromised immune systems and cystic fibrosis (CF); over 80% of CF patients die from these infections [@bib1]. *P. aeruginosa* is naturally resistant to a large range of antibiotics (cephalosporins, carbapenems, fluoroquinolones, and aminoglycosides) and may demonstrate additional resistance after unsuccessful treatment [@bib2]. Some new strategies have been developed because of unsatisfactory traditional antibiotic treatment, including inhibition of the pathogenic factors of *P. aeruginosa* [@bib3].

The main pathogenic factors of *P. aeruginosa* include elastase, alkaline protease, LasA protease, hemolysin, rhamnolipids and pyocyanin (5-methyl-1-hydroxyphenazine) (PCN) [@bib4]. PCN, a blue colored phenazine exotoxin, can easily penetrate biological membranes and is found in the sputum of CF patients infected by *P. aeruginosa* [@bib5]. Recent in vivo studies on alternative model hosts [@bib6] and mice [@bib7] have revealed that PCN is a key compound in *P. aeruginosa* infections and is a significant contributor to lung destruction during chronic *P. aeruginosa* infection in patients with bronchiectasis. PCN inhibits the ciliary beating of airway epithelial cells and enhances superoxide production [@bib8].

Nitric oxide (NO) not only is important as a biological messenger but also has many biological effects [@bib9]. Excessive exogenous NO can damage proteins, nucleic acids, and cellular membranes when the concentration of NO exceeds the capacity of cell metabolism. Nitric oxide reductase (NOR) is a common respiratory enzyme in eukaryotic cells and bacteria [@bib10] that catalyzes the endogenous NO to N~2~O. The enzyme is involved in the denitrification pathway of *P. aeruginosa* by dissimilatory nitrate respiration [@bib11]. If NO is not reduced by NOR to N~2~O, it may accumulate, and its toxicity could compromise bacteria. Therefore, the respiratory enzyme NOR is also a detoxifying enzyme. In other words, the enzyme is involved in the defense against exogenous NO in their surrounding natural habitats and within their hosts [@bib12]. This enzyme is part of a cytochrome bc-type complex in *P. aeruginosa*. The *nor*C and *nor*B genes, encoding the cytochrome *c* and cytochrome *b* subunits, respectively, are clustered with the *nor*D gene, which is required for the expression of the active NOR enzyme [@bib13].

Recent research has shown that a high concentration of NO can inhibit the growth of *E. coli* [@bib14]; however, sublethal concentrations of NO plays a great role in *P. aeruginosa* biofilm dispersal and helps in the biofilm mode of growth transition to the free-swimming planktonic state [@bib15]. Is there any other effect of NO on *P. aeruginosa*? Based on this question, we tested the PCN biosynthesis of *P. aeruginosa* in the presence of different concentrations of the NO donor sodium nitroprusside (SNP). Both SNP and *nor* gene knockout mutants could effectively inhibit the synthesis of PCN in *P. aeruginosa.*

2. Material and methods {#s0010}
=======================

2.1. Bacterial isolates {#s0015}
-----------------------

Four clinical isolates of *P. aeruginosa* were collected from Shanxi Province People's Hospital in China ([Table 1](#t0005){ref-type="table"}). The *P. aeruginosa* strains were isolated from urine (1) and sputum (3) samples. We also used the reference PAO1 strain as the main lab strain. The PAO1 strain was kindly provided by Professor Kangmin Duan (Department of Medical Microbiology, University of Manitoba, Canada).

2.2. Growth test {#s0020}
----------------

A 10 ml overnight culture of PAO1 was grown in LB medium (10% peptone, 5% yeast extract and 10% NaCl) at 37 °C on an orbital shaker at 200 rpm. The OD600 nm was adjusted to 0.1 using sterile LB and vortexed. Then, 100 μl was added to culture tubes containing 50 ml of LB medium. Next, sodium nitroprusside (SNP) was added to the LB in the tubes at the desired concentrations. For the untreated control, no SNP was added. The cultures were grown aerobically at room temperature on an orbital shaker at 200 rpm for 18--22 h. The growth was followed by measurement at OD600 nm every 2 h.

2.3. DNA manipulations {#s0025}
----------------------

Chromosomal and plasmid DNA extraction, purification, enzymatic digestion, DNA ligation, and transformation of *Escherichia coli* were performed according to standard methods [@bib16]. PCR was conducted using Taq polymerase (TaKaRa Japan) on an ABI PCR system. The following PCR program was used: 5 min at 95 °C and 30 cycles of 30 seconds at 95 °C, 30 seconds at annealing temperature (5 °C below the melting point), and 1 to 3.5 min (according to the size of the fragments) at 72 °C; 10 min at 72 °C; and then storage at 4 °C. The nucleotide and predicted amino acid sequences were analyzed using DNASTAR and compared with the GenBank database using BLAST (<http://www.ncbi.nlm.nih.gov/BLAST/>).

2.4. Construction of *P. aeruginosa* PAO1 and PA515 *nor* gene knockout mutants {#s0030}
-------------------------------------------------------------------------------

Protocols for DNA manipulation, cloning, reporter strain construction, and plasmid and chromosomal DNA purifications were obtained from Sambrook et al. [@bib16]. Enzymes were purchased from either TaKaRa Japan or Promega USA. Two oligonucleotide primers were designed on the basis of the sequences flanking the *nor* genes of *P. aeruginosa* [@bib17]. The *nor* genes of *P. aeruginosa* were amplified by PCR from chromosomal DNA using the primer combinations NorEF (GTAGAATTCCTGGTCTACGTCCTGCAATGAG) and NorHR (GTGAAGCTTCCGATGAGGAACACCACCC). The amplified fragments were subsequently cloned into pMD18-T (TaKaRa) and sequenced. To avoid errors introduced by PCR, the DNA inserts from three individual clones were sequenced and compared. The *nor* genes consensus sequences from *P. aeruginosa* were compared to the nitric oxide reductase genes available in the GenBank database. For construction of the gene knockout mutants, a SacB-based strategy was employed [@bib18]. The PCR product of the *nor* gene was digested with EcoRI and HindIII (site underlined in the primer sequences) and cloned into pEX18Amp. To construct the *nor* mutant, the DNA fragment containing the Gmr-lacZ from pZ1918Gm was inserted into the target genes. The final plasmid, named pEXB1lacZ, was verified by PCR and enzyme digestion. pEXBlacZ was introduced into *P. aeruginosa* by triparental mating [@bib19], and *nor* was disrupted by integration of pEXBlacZ into the chromosome. The bacterial strains and plasmids used in this study are described in [Table 1](#t0005){ref-type="table"}.

2.5. PCN assay {#s0035}
--------------

*P. aeruginosa* was inoculated into 1 L of LB medium and incubated at 37 °C in a shaking incubator at 150 rpm. The blue-colored broth (due to the presence of PCN) was transferred into 50-ml Oakridge tubes and centrifuged at 10,000*g* for 20 min at 4 °C. The supernatant was transferred to a separating funnel and mixed with chloroform in a 1:1.5 (supernatant: chloroform) ratio. This mixture was shaken well and maintained undisturbed for 5--10 min to extract the PCN into the chloroform. The blue colored chloroform layer with PCN formed below the aqueous layer in the separating funnel was collected in a conical flask protected from light to prevent oxidation. This chloroform fraction was then transferred to a 500-mL vacuum rotary flask and concentrated in a vacuum rotary evaporator at 40 °C. The vacuum concentrated PCN fraction was purified using a silica gel column 3 cm in diameter and 60 cm in length. The column was packed with silica (mesh size 100--200) and equilibrated using a methanol-chloroform solvent system at a ratio of 1:1, and the concentrated PCN fraction was loaded onto the column. Methanol:chloroform (1:1) was used as the mobile phase to separate the PCN. The chloroform phase was then added to 0.2 N HCl (0.2 mL), which produced a pink to deep red color that is indicative of the presence of PCN [@bib20]. The absorbance was measured at 520 nm, and the PCN concentrations were calculated.

2.6. Statistical analysis {#s0040}
-------------------------

The statistical significance for differences in this study was based on Student\'s two-tailed *t*-test. Differences were considered significant when the *P*-value was less than 0.05.

3. Results {#s0045}
==========

3.1. Effect of SNP on growth and PCN levels in *P. aeruginosa* {#s0050}
--------------------------------------------------------------

First, we tested the effect of the exogenous NO on growth. PAO1 was cultured in the presence of a range of concentrations (20, 60, 100, 140, 160 and 200 μM) of the NO donor SNP for the 18 h culture ([Fig. 1](#f0005){ref-type="fig"}A). Compared with the control (no SNP), the reduction rates for 20 μM, 60 μM, 100 μM, 140 μM, 160 μM, and 200 μM were 6.3%, 7.9%, 8.2%, 12.1%, 24.9%, and 25.8%, respectively. These results showed that the growth reduction was not strong at SNP concentrations below 100 μM. Then, we chose the SNP concentration below 100 μM for the PCN assay in which growth was not strongly inhibited. We measured PCN levels at a range of SNP concentrations (20, 40, 60, 80 and 100 μM). After the 18 h culture period, the reduction rates for 20 μM, 40 μM, 60 μM, 80 μM, and 100 μM were 45.4%, 65.1%, 82.5%, 83.1%, and 83.5%, respectively ([Fig. 1](#f0005){ref-type="fig"}B and C). The reduction ratios (PCN reduction:Growth reduction) were calculated, and the ratios for 20 μM, 60 μM, and 100 μM were 7.2, 10.5, and 9.7, respectively. From the results, we chose 60 μM SNP as the treatment condition in the subsequent tests because the maximum ratio was found at 60 μM SNP.

To examine whether the results were universal to other *P. aeruginosa* strains, four clinical strains were selected from Shaanxi Province People\'s Hospital ([Table 2](#t0010){ref-type="table"}). The growth and PCN levels were examined. Similar to the results for PAO1 that showed 7.9% lower growth with 60 μM SNP after 18 h culture, the growth reduction rates in the 4 clinical strains were 6.1% for PA515, 8.8% for PA516, 5.2% for PA554, and 5.7% for PA914 ([Fig. 2](#f0010){ref-type="fig"}A). Similar to the results for PAO1 (82.5% reduction of PCN), the reduction of PCN in the 4 clinical strains exposed to 60 μM SNP for 18 h showed strong reductions in PCN levels (PCN reduction rate: 78.3% for PA515, 89.1% for PA516, 76.0% for PA554, and 70.8% for PA914) ([Fig. 2](#f0010){ref-type="fig"}B). The reduction ratios (PCN reduction:Growth reduction) were also calculated. The ratios were 10.5 for PAO1, 12.8 for PA515, 10.1 for PA516, 14.5 for PA554, and 12.4 for PA914.

Compared with PAO1, the clinical strains had the same trend for PCN reduction with low, sublethal concentrations of NO. All of the data are presented as the mean±SD (*n*=4) and have been validated 4 times by experiments that had similar results.

3.2. Construction of *P. aeruginosa* PAO1 and PA515 *nor* gene knockout mutants {#s0055}
-------------------------------------------------------------------------------

Based on the results for the exogenous NO, we tested the effect of endogenous NO on PCN levels in *P. aeruginosa*. Considering that the deletion of Nor lead to the accumulation of endogenous NO, the test was conducted by constructing *nor* mutants. First, to examine whether the *nor* gene were universal to *P. aeruginosa* strains, we analyzed the *nor* sequence in PAO1 and clinical strains by PCR and sequencing, and the results showed that these strains possessed the same *nor* gene sequences as PAO1. Considering the restriction sites and the plasmid available, we chose to delete the *nor*BC gene. The gentamicin-resistance cassette was inserted into the *nor*BC region by homologous recombination, which resulted in deletion of *nor*B and *nor*C. The restriction sites used for the construction are shown ([Fig. 3](#f0015){ref-type="fig"}A). Five gentamicin-resistant clones were analyzed by PCR ([Fig. 3](#f0015){ref-type="fig"}B). We designed 3 primers, including two end sequences of the target fragment, and a sequence in the replacement fragment. As shown in [Fig. 3](#f0015){ref-type="fig"}B, when PCR was conducted with the two ends primers, on the agarose gel only wild strains had the band, while the mutant strains and the plasmid had no bands; when using the primer in the replacement fragment for PCR, the result was reversed, and only mutant strains and the plasmid had the target band, and the wild strain did not. Then, we conducted a resistance test ([Fig. 3](#f0015){ref-type="fig"}C), and only the mutant strains carrying the resistance gene could grow in the resistance medium. Finally, we sequenced the insert fragment and confirmed that the *norBC* region was correctly replaced by Gm resistance gene in all of the clones. One of these clones was named PAN1 (*nor* mutant) and used for the subsequent experiments. To examine whether the results were universal for the other *P. aeruginosa* strains, we chose one of the clinical strains (PA515) to construct the *nor* mutant strain (PAN515) using the same procedure.

3.3. Effect of NOR enzyme deletions on the growth and PCN levels of *P. aeruginosa* {#s0060}
-----------------------------------------------------------------------------------

Based on the construction of the *nor* mutants, we first tested the growth of the *PAO1* wild-type and *nor* mutants. The growth curves of the *PAO1* wild-type and *nor* mutants for 22 h are shown in [Fig. 4](#f0020){ref-type="fig"}A. The difference in growth began at the exponential phase and was 14% at the end of this phase. In the stagnate phase, the difference decreased; the minimum difference was 6% at 18 h, and the maximum difference was 10% at 22 h. In the whole culture, the *nor* mutants grew slightly slower than the wild-type. The same growth test was carried out in PA515 wild-type and *nor* mutants ([Fig. 4](#f0020){ref-type="fig"}B). The difference in growth began at the exponential phase, which was 8% at the end of this phase. However, unlike PAO1, in the stagnate phase, the difference did not decrease, and the difference was maintained at approximately 8% until 22 h. From the results, it is clear that the *nor* gene did not have a strong effect on growth.

Then, we compared the levels of the PCN of *PAO1* wild-type and *nor* mutants ([Fig. 5](#f0025){ref-type="fig"}A). After the 6 h culture, the two strains exhibited normal color with hardly any PCN. However, after 8 h, the PCN in the *nor* mutants was significantly lower than that in the wild-type. The PCN difference strictly increased until 18 h. After 18 h, the difference was maintained, and the maximum PCN reduction observed was 86% in PAN1 compared to PAO1 at 22 h ([Fig. 5](#f0025){ref-type="fig"}A). The same PCN test was conducted on PA515 wild-type and *nor* mutants. After a 6 h culture, the two strains exhibited normal color with hardly any PCN. After 8 h, the PCN in the *nor* mutants was significantly lower than that in the wild-type. However, unlike PAO1, the PCN difference strictly increased until 24 h. The observed PCN reduction was 85.2% in PAN515 compared to the PA515 at 22 h ([Fig. 5](#f0025){ref-type="fig"}B). The reduction ratio (PCN reduction: growth reduction) was also calculated. The ratios were 8.6 for PAN1 and 10.6 for PAN515.

The results show that the PCN biosynthesis weakened the NOR-deficient mutants when compared with wild-type strains. All of the data are presented as the mean±SD (*n*=4) and have been validated 4 times by experiments with similar results.

4. Discussion {#s0065}
=============

PCN not only interferes with multiple cellular functions, it is also required in *P. aeruginosa* clinical infections, which can kill lung epithelial cells [@bib7]. One of the strategies to overcome *P. aeruginosa* virulence is to inhibit PCN biosynthesis by antioxidant therapy that neutralizes PCN-generated oxidative stress [@bib21]. Smith et al. presented a pathway in *P. aeruginosa* that is disrupted during anti-PCN therapy [@bib22].

In this study, we investigated the effect of NO on PCN biosynthesis in *P. aeruginosa*. Unlike the minor effect on growth at a range of SNP concentrations (20--100 μM), the PCN biosynthesis was strongly inhibited with the increase in SNP. This trend was similar in PAO1 (the mode strain of *P. aeruginosa*) and 4 clinical strains (PCN reduction: 82.5% in PAO1, 78.3% in PA515, 89.1% in PA516, 76.0% in PA554, and 70.8% in PA914). Furthermore, we observed up to an 82.5% reduction in PCN biosynthesis with the 60 μM NO donor, whereas the reported reduction via other compounds was lower: 50% reduction with catechin (2--4 mM) [@bib23], 56% with eugenol (at 50--400 μM) [@bib24], and 76.5% with 2.5 g/L of Yunnan Baiyao, which is a well-known Chinese herbal medicine [@bib25]. The results suggest that NO exerts better anti-virulence activity by interfering with PCN biosynthesis in *P. aeruginosa*.

In addition to the exogenous compound, some research shows that deleting certain genes can inhibit PCN biosynthesis. ΔBpiB09 (an NADP-dependent reductase) mutants reportedly produce up to 75% lower PCN than the wild-type after 16 h of growth [@bib26]. In this study, we analyzed the effect of the *nor* gene, which coded the nitric oxide reductase, on PCN biosynthesis. Nitric oxide reductase is a key enzyme that catalyzes endogenous NO and reduces it to N~2~O. The deletion of *nor* will induce endogenous NO accumulation. We first analyzed the *nor* sequence in clinical strains ([Table 2](#t0010){ref-type="table"}) by PCR and gene sequencing, and the results showed that these strains processed the same *nor* gene sequences, such as PAO1, which suggested that the *nor* sequence in *P. aeruginosa* is conservative. Then, the effects of endogenous NO on PCN in *P. aeruginosa* were tested by constructing NOR-deficient mutants. Our results showed that PCN biosynthesis was weakened in the NOR-deficient mutants (86% reduction in PAN1, 85.2% in PAN515) when compared with the wild-type strains. These results indicate that the accumulation of endogenous NO by deleting *nor* strongly inhibits PCN biosynthesis in *P. aeruginosa*.

In summary, both exogenous and endogenous NO can significantly reduce PCN production in *P. aeruginosa* as well as in clinical strains. These results suggest that we may use an NO donor or selective inhibition of NOR to eliminate *P. aeruginosa* virulence through inhibition of PCN biosynthesis. Further studies are required to determine the specific molecular mechanism involved. Previous studies have shown that NO participates in diverse biological processes [@bib27]. It acts through redox-based modification of cysteine residue(s) of target proteins, called protein S-nitrosation. Seth et al. have demonstrated that S-nitrosylation of OxyR under anaerobic condition in *E. coil* can activate *hcp* transcription to protect against endogenous nitrosative stress [@bib14]. PCN is synthesized through a series of complex steps including gene expression and modification from precursors into the tricyclic compound mediated by many key enzymes [@bib3]. We have found that total protein *S*-nitrosation significantly increased when *P. aeruginosa* are exposed to NO (data not shown). We speculate that some proteins involving in PCN biosynthesis might be modified by NO, which is perhaps crucial to the PCN reduction. Further investigation is undergoing.
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![The effect of SNP on the growth and PCN of PAO1. (A) A growth test on PAO1: a liquid culture of PAO1 was grown in LB medium at 37 °C and at 200 rpm for 18 h. The NO donor compound in LB was added to the medium at the desired concentration. The OD600 values were determined every 2 h. (B) The PCN test on PAO1: the PAO1 were seeded onto LB agar and exposed to the indicated concentration of SNP. After 14 h, the samples were scanned for the color of the medium. (C) The PCN assay on PAO1: the medium was mixed with chloroform, and the chloroform phase was then added to 0.2 N HCl. The absorbance was measured at 520 nm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}

![Growth and PCN reduction of clinical *P. aeruginosa* strains with 60 μM SNP. (A) A growth test on clinical *P. aeruginosa* strains: a liquid culture of clinical strains was grown in LB medium at 37 °C and at 200 rpm for 18 h. The 60 μM NO donor compound in LB was added to the medium. The OD600 values at 18 h were determined. (B) The PCN assay on clinical *P. aeruginosa* strains: the medium was mixed with chloroform, and the chloroform phase was then added to 0.2 N HCl. The absorbance was measured at 520 nm.](gr2){#f0010}

![PCR and antibiotic resistance test. (A) A construction of the *nor*BC mutant strain of *P. aeruginosa*. The gentamicin-resistance cassette was inserted into the *nor*BC region by homologous recombination, which resulted in total deletion of *nor*B and partial deletion of *nor*C. The restriction sites used for the construction are shown. GmR, gentamicin resistance. (B) The PCR test: Lane 1: the PCR product of pEXB1lacZ using the NOREF/NORHR primer; Lane 2: the PCR product of PAN1 using the NOREF/NORHR primer; Lane 3: the PCR product of the PAN1 (parallel sample) strain using the NOREF/NORHR primer; Lane 4: the PCR product of PAO1 using the NOREF/NORHR primer; Lane 5: Marker; Lane 6: the PCR product of pEXB1lacZ using the lacZ-F/NORHR primer; Lane 7: the PCR product of PAN1 using the lacZ-F/NORHR primer; Lane 8: the PCR product of PAN1 (parallel sample) using the lacZ-F/NORHR primer; Lane 9: the PCR product of PAO1 using the lacZ-F/NORHR primer; (C) The antibiotic resistance test: (C1) growth of PAO1 and its disruption mutants on PIA medium containing Gm (only PAN1 could grow); and (C2) growth of PAO1 and its disruption mutants on PIA medium (no antibiotic was added, and all of the strains could grow well on it).](gr3){#f0015}

![The effect of Nor on the growth of PAO1 and PA515. (A) The growth test for PAO1 and PAN1: liquid cultures of PAO1 and PAN1 were grown in LB medium at 37 °C and at 200 rpm for 22 h. OD600 values were determined every 2 h. (B) The growth test for PA515 and PAN515: liquid cultures of PA515 and PAN515 were grown in LB medium at 37 °C and at 200 rpm for 22 h. The OD600 values were determined every 2 h.](gr4){#f0020}

![The effect of Nor on the PCN produced by PAO1 and PA515. A. The PCN assay for PAO1 and PAN1: liquid cultures of PAO1 and PAN1 were grown in LB medium at 37 °C and at 200 rpm for 24 h. The medium was mixed with chloroform, and the chloroform phase was then added to 0.2 N HCl. The absorbance was measured at 520 nm. B. The PCN assay for PA515 and PAN515: liquid cultures of PA515 and PAN515 were grown in LB medium at 37 °C and at 200 rpm for 24 h. The medium was mixed with chloroform, and the chloroform phase was then added to 0.2 N HCl. The absorbance was measured at 520 nm. C: A picture of PCN in the chloroform layer (PAO1: left; PAN1: right). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr5){#f0025}

###### 

List of strains and plasmids used in this study.

Table 1

  **Strain or plasmid**            **Characteristic(s)**[a](#tbl1fna){ref-type="table-fn"}                                                               **Source or reference**
  -------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------------------
  **Strains**                                                                                                                                            
    ***Escherichia coli***                                                                                                                               
    DH5α                           F- mcrA Δ(mrr-hsdRMS-mcrBC), Φ 80 lacZ ΔM15 ΔlacX74 recA1 endA1 araD139 Δ(ara,leu) 7697 galU galK λ- rpsL nupG tonA   Invitrogen
    ***Pseudomonas aeruginosa***                                                                                                                         
    PAO1                           Wild type, lab strain                                                                                                 This study
    PAN1                           *nor* insertion mutant, GmR                                                                                           This study
    PA515                          Wild type, clinical strain                                                                                            Clinic
    PAN515                         *nor* insertion mutant, GmR                                                                                           This study
    PA196                          Wild type, clinical strain                                                                                            Clinic
    PA554                          Wild type, clinical strain                                                                                            Clinic
    PA914                          Wild type, clinical strain                                                                                            Clinic
  **Plasmids**                                                                                                                                           
    pEX18Amp                       oriT^+^sacB^+^ gene replacement vector with multiple-cloning site from pUC18, AmpR                                    [@bib18]
    pHpΏ45                         Sm^r^/Spc^r^ gene from the R100.1 plasmid, transcription-termination sequences from pMJK4-18 plasmid, SmR/SpcR        [@bib28]
    pZ1918Gm                       Source plasmid of Gm^r^ cassette, GmR                                                                                 [@bib29]
    pRK2013                        Broad-host-range helper vector, KanR                                                                                  [@bib19]
    pEXB                           pEX18Amp containing a *nor* fragment, AmpR                                                                            This study
    pEXB1lacZ                      pEXB1 containing Gm^r^-lacZ fragment from pZ1918Gm insert in the *Sph*I site, AmpR/GmR                                This study

Antibiotic resistance markers: AmpR ampicillin, GmR gentamicin, KanR kanamycin.

###### 

List of clinical strains used in this study.

Table 2

  **Strain**   **Gender**   **Age**   **Source**   **Diagnose**
  ------------ ------------ --------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PA515**    Male         63        Sputum       Pulmonary infection, closed craniocerebral injury
  **PA516**    Male         76        Sputum       Aspiration pneumonia and coronary atherosclerotic heart disease, bottom wall myocardial infarction (mi), Parkinson's disease, hyperplasia of prostate, neurogenic bladder, moderate anemia
  **PA554**    Male         85        Sputum       Cerebral infarction, lung infection repeatedly, carotid atherosclerosis, hypertension
  **PA914**    Male         42        Urine        Urinary tract infection, urinary bladder fistula, postoperative rectal cancer, postoperative left renal cyst, hyperplasia of prostate

[^1]: Contributed equally.
